169 related articles for article (PubMed ID: 28827745)
21. Detecting circulating tumor DNA in renal cancer: An open challenge.
Corrò C; Hejhal T; Poyet C; Sulser T; Hermanns T; Winder T; Prager G; Wild PJ; Frew I; Moch H; Rechsteiner M
Exp Mol Pathol; 2017 Apr; 102(2):255-261. PubMed ID: 28214514
[TBL] [Abstract][Full Text] [Related]
22. Optimisation of robust singleplex and multiplex droplet digital PCR assays for high confidence mutation detection in circulating tumour DNA.
Rowlands V; Rutkowski AJ; Meuser E; Carr TH; Harrington EA; Barrett JC
Sci Rep; 2019 Sep; 9(1):12620. PubMed ID: 31477768
[TBL] [Abstract][Full Text] [Related]
23. [Detection of KRAS mutation in colorectal cancer patients' cfDNA with droplet digital PCR].
Luo Y; Li Y
Sheng Wu Gong Cheng Xue Bao; 2018 Mar; 34(3):407-420. PubMed ID: 29577691
[TBL] [Abstract][Full Text] [Related]
24. Clinical validation of qPCR Target Selector™ assays using highly specific switch-blockers for rare mutation detection.
Arnold L; Alexiadis V; Watanaskul T; Zarrabi V; Poole J; Singh V
J Clin Pathol; 2020 Oct; 73(10):648-655. PubMed ID: 32132121
[TBL] [Abstract][Full Text] [Related]
25. Potential of modern circulating cell-free DNA diagnostic tools for detection of specific tumour cells in clinical practice.
Gašperšič J; Videtič Paska A
Biochem Med (Zagreb); 2020 Oct; 30(3):030504. PubMed ID: 32774122
[TBL] [Abstract][Full Text] [Related]
26. Monitoring KRAS mutations in circulating DNA and tumor cells using digital droplet PCR during treatment of KRAS-mutated lung adenocarcinoma.
Guibert N; Pradines A; Farella M; Casanova A; Gouin S; Keller L; Favre G; Mazieres J
Lung Cancer; 2016 Oct; 100():1-4. PubMed ID: 27597273
[TBL] [Abstract][Full Text] [Related]
27. International pilot external quality assessment scheme for analysis and reporting of circulating tumour DNA.
Keppens C; Dequeker EMC; Patton SJ; Normanno N; Fenizia F; Butler R; Cheetham M; Fairley JA; Williams H; Hall JA; Schuuring E; Deans ZC;
BMC Cancer; 2018 Aug; 18(1):804. PubMed ID: 30092778
[TBL] [Abstract][Full Text] [Related]
28. A Study of Pre-Analytical Variables and Optimization of Extraction Method for Circulating Tumor DNA Measurements by Digital Droplet PCR.
Cavallone L; Aldamry M; Lafleur J; Lan C; Gonzalez Ginestet P; Alirezaie N; Ferrario C; Aguilar-Mahecha A; Basik M
Cancer Epidemiol Biomarkers Prev; 2019 May; 28(5):909-916. PubMed ID: 30824523
[TBL] [Abstract][Full Text] [Related]
29. [Clinical implications of the concentration and EGFR/KRAS mutations of plasma cell free DNA of patients with lung cancer and esophageal cancer].
Zhang R; Li Y; Chen Y; Liu X; Wang Z; Sun H; Zheng Y; Ding Z; Lan L; Li M; Qin J; Chen X
Zhonghua Yi Xue Za Zhi; 2015 Dec; 95(47):3839-42. PubMed ID: 27337801
[TBL] [Abstract][Full Text] [Related]
30. [Establishment of a novel TB-ARMS qPCR method for kras mutation detection].
Yu L; Teng F; Jiang M; Guo J
Sheng Wu Gong Cheng Xue Bao; 2019 May; 35(5):880-891. PubMed ID: 31223006
[TBL] [Abstract][Full Text] [Related]
31. Levels of cell-free DNA and plasma KRAS during treatment of advanced NSCLC.
Dowler Nygaard A; Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
Oncol Rep; 2014 Feb; 31(2):969-74. PubMed ID: 24316734
[TBL] [Abstract][Full Text] [Related]
32. Correlation of genomic alterations between tumor tissue and circulating tumor DNA by next-generation sequencing.
Chang YS; Fang HY; Hung YC; Ke TW; Chang CM; Liu TY; Chen YC; Chao DS; Huang HY; Chang JG
J Cancer Res Clin Oncol; 2018 Nov; 144(11):2167-2175. PubMed ID: 30203147
[TBL] [Abstract][Full Text] [Related]
33. Highly sensitive and specific real-time PCR by employing serial invasive reaction as a sequence identifier for quantifying EGFR mutation abundance in cfDNA.
Xiang Z; Wan R; Zou B; Qi X; Huang Q; Kumar S; Pitman JL; Zhou G; Song Q
Anal Bioanal Chem; 2018 Oct; 410(26):6751-6759. PubMed ID: 30128808
[TBL] [Abstract][Full Text] [Related]
34. Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective.
Postel M; Roosen A; Laurent-Puig P; Taly V; Wang-Renault SF
Expert Rev Mol Diagn; 2018 Jan; 18(1):7-17. PubMed ID: 29115895
[TBL] [Abstract][Full Text] [Related]
35. Circulating free DNA as biomarker and source for mutation detection in metastatic colorectal cancer.
Spindler KL; Pallisgaard N; Andersen RF; Brandslund I; Jakobsen A
PLoS One; 2015; 10(4):e0108247. PubMed ID: 25875772
[TBL] [Abstract][Full Text] [Related]
36. The feasibility of using mutation detection in ctDNA to assess tumor dynamics.
Yi X; Ma J; Guan Y; Chen R; Yang L; Xia X
Int J Cancer; 2017 Jun; 140(12):2642-2647. PubMed ID: 28124376
[TBL] [Abstract][Full Text] [Related]
37. Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients.
Ashida A; Sakaizawa K; Uhara H; Okuyama R
Acta Derm Venereol; 2017 Nov; 97(10):1212-1218. PubMed ID: 28681063
[TBL] [Abstract][Full Text] [Related]
38. Dynamic changes of circulating tumour DNA in surgical lung cancer patients: protocol for a prospective observational study.
Chen K; Zhao H; Yang F; Hui B; Wang T; Wang LT; Shi Y; Wang J
BMJ Open; 2018 Feb; 8(2):e019012. PubMed ID: 29437753
[TBL] [Abstract][Full Text] [Related]
39. Non-blood sources of cell-free DNA for cancer molecular profiling in clinical pathology and oncology.
Ponti G; Manfredini M; Tomasi A
Crit Rev Oncol Hematol; 2019 Sep; 141():36-42. PubMed ID: 31212145
[TBL] [Abstract][Full Text] [Related]
40. IQN path ASBL report from the first European cfDNA consensus meeting: expert opinion on the minimal requirements for clinical ctDNA testing.
Deans ZC; Butler R; Cheetham M; Dequeker EMC; Fairley JA; Fenizia F; Hall JA; Keppens C; Normanno N; Schuuring E; Patton SJ
Virchows Arch; 2019 Jun; 474(6):681-689. PubMed ID: 31028539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]